Philip Larsen
Senior Vice President & Global Head of Research & Early Development Bayer
Seminars
Wednesday 28th October 2026
Exploring GIP Pathways to Combat Obesity & Diabetes to Decrease Comorbidities
11:15 am
- Analysing the GIP pathway to identify opportunities to leverage GIP antagonism for diabetes treatments as a comorbidity of obesity
- Highlighting data showcasing robust effects in type 2 diabetes and insulin sensitivity improvement when GIP is combined with GLP-1 to expand indication treatment opportunities
